- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Applying Third-Line Therapy in mCRC: Community vs Academic Settings
Panelists discuss how community and academic settings differ in applying third-line therapies for metastatic colorectal cancer and how collaboration benefits patients.
EP: 1.Overview of Available Third-Line Options in mCRC
EP: 2.Evidence Supporting FTD/TPI ± Bevacizumab in mCRC
EP: 3.Efficacy of Fruquintinib and Comparisons Across Agents in mCRC
EP: 4.Selecting Among Third-Line Therapies in Clinical Practice for mCRC
EP: 5.Leveraging Real-World Evidence in Sequencing Decisions for mCRC
EP: 6.Translating Real-World Outcomes in mCRC Into Patient Conversations
EP: 7.Incorporating Patient-Reported Outcomes in mCRC Into Shared Decision-Making
EP: 8.Real-World Evidence in mCRC: Special Populations and Safety Assessment
EP: 9.Defining Future Needs for Real-World Evidence in mCRC
EP: 10.Applying Third-Line Therapy in mCRC: Community vs Academic Settings
Panelists describe clinical scenarios where patients may receive third-line therapy in community vs academic settings, noting differences in resources, expertise, and support.
Community practices may offer more accessibility and continuity of care, whereas academic centers may be better suited for complex cases or clinical trial enrollment.
They emphasize the importance of collaboration between settings to ensure equitable and consistent care for patients, regardless of treatment location.
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
November 11th 2025Cefdinir is linked to nearly double the outpatient uncomplicated UTI treatment failure of cephalexin, with higher recurrence and increased resistance to other cephalosporins.
Read More
